Supplementary Table 3. Patient baseline characteristics and lipid profiles, and LLT post ACS and change in LDL-C: subgroup analysis by quartile of absolute LDL-C change from the first measurement after hospitalization to Visit 3 § .
| All patients ( n = 1,411) |
Q1 ( n = 328) |
Q2 ( n = 338) |
Q3 ( n = 338) |
Q4 ( n = 337) |
P -value | |
|---|---|---|---|---|---|---|
| Age, years, mean (SD) | 66.0 (12.1) | 61.4 (12.2) | 65.7 (12.0) | 67.2 (11.6) | 69.5 (11.4) | ＜0.001 |
| Male, n (%) | 1,135 (80.4) | 272 (82.9) | 274 (81.1) | 269 (79.6) | 260 (77.2) | 0.291 |
| BMI, kg/m 2 , mean (SD) | 24.2 (3.5) | 24.9 (3.4) | 24.4 (3.4) | 23.9 (3.7) | 23.6 (3.3) | ＜0.001 |
| ACS type, n (%) | 0.007 | |||||
| STEMI | 871 (61.7) | 228 (69.5) | 216 (63.9) | 203 (60.1) | 188 (55.8) | |
| UA | 314 (22.3) | 59 (18.0) | 63 (18.6) | 75 (22.2) | 92 (27.3) | |
| Non-STEMI | 226 (16.0) | 41 (12.5) | 59 (17.5) | 60 (17.8) | 57 (16.9) | |
| eGFR ＜15 mL/min/1.73 m 2 , n (%) | 23 (1.7) | 0 (0.0) | 3 (0.9) | 5 (1.5) | 15 (4.5) | 0.002 |
| LDL-C, mean (SD), mg/dL, first measurement # | 121.5 (39.0) | 167.6 (33.8) | 125.4 (19.8) | 105.7 (22.2) | 88.7 (25.2) | ＜0.001 |
| Baseline lipid profile (Visit 1), mg/dL | ||||||
| LDL-C, mean (SD), calculated | 98.8 (30.9) | 116.6 (38.2) | 98.6 (25.7) | 91.5 (24.3) | 87.3 (25.5) | ＜0.001 |
| HDL-C, mean (SD) | 41.2 (11.6) | 39.8 (11.1) | 40.7 (10.5) | 42.3 (12.9) | 41.9 (11.7) | 0.026 |
| Triglycerides, median (min, max) | 108 (25, 552) | 121 (31, 552) | 106 (39, 337) | 106 (25, 436) | 101 (36, 441) | ＜0.001 |
| Total cholesterol, mean (SD) | 164.0 (37.2) | 183.8 (45.3) | 162.9 (31.0) | 156.8 (30.9) | 151.0 (31.0) | ＜0.001 |
| History of CV risk factors/comorbidities, n (%) | ||||||
| Dyslipidemia | 1,109 (78.6) | 286 (87.2) | 251 (74.3) | 251 (74.3) | 267 (79.2) | ＜0.001 |
| Hypertension | 1,040 (73.7) | 224 (68.3) | 241 (71.3) | 260 (76.9) | 262 (77.7) | 0.014 |
| Diabetes mellitus | 465 (33.0) | 97 (29.6) | 101 (29.9) | 112 (33.1) | 133 (39.5) | 0.022 |
| Smoking | ＜0.001 | |||||
| Current smoker | 525 (37.2) | 151 (46.0) | 127 (37.6) | 115 (34.0) | 106 (31.5) | |
| Previous smoker | 410 (29.1) | 79 (24.1) | 110 (32.5) | 108 (32.0) | 94 (27.9) | |
| None | 476 (33.7) | 98 (29.9) | 101 (29.9) | 115 (34.0) | 137 (40.7) | |
| Coronary artery disease | 255 (18.1) | 26 (7.9) | 39 (11.5) | 71 (21.0) | 105 (31.2) | |
| Cerebrovascular accident | 100 (7.1) | 20 (6.1) | 20 (5.9) | 21 (6.2) | 31 (9.2) | |
| Dialysis | 20 (1.4) | 0 (0.0) | 4 (1.2) | 4 (1.2) | 11 (3.3) | |
| Peripheral artery disease | 27 (1.9) | 2 (0.6) | 3 (0.9) | 8 (2.4) | 13 (3.9) | |
| LLT at Visit 1 ( n / N ), n (%) | ||||||
| Statin | 321/325 (98.8) | 326/333 (97.9) | 317/331 (95.8) | 295/334 (88.3) | ||
| Intensive statin | 58/325 (17.8) | 18/333 (5.4) | 27/331 (8.2) | 17/334 (5.1) | ||
| Ezetimibe | 38/326 (11.7) | 17/333 (5.1) | 15/331 (4.5) | 14/334 (4.2) | ||
| Change in LDL-C from first measurement after hospitalization to Visit 1 | ||||||
| Number | 328 | 338 | 338 | 337 | ||
| mg/dL, mean (SD) | −93.1 (25.0) | −51.0 (7.7) | −25.6 (7.5) | 9.5 (19.2) |
§ Evaluated patients with available and changed LDL-C measurement at Visit 3.
# At first measurement after hospitalization.
Visit 1 was within 14 days of hospitalization for ACS.
ACS, acute coronary syndrome; BMI, body mass index; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; SD, standard deviation; STEMI, ST-segment- elevation myocardial infarction; UA, unstable angina.